{"id":"spironolactone-beta-blockers-ecc","safety":{"commonSideEffects":[{"rate":"5-10","effect":"Hyperkalemia"},{"rate":"10-15","effect":"Fatigue"},{"rate":"5-10","effect":"Dizziness"},{"rate":"5-10","effect":"Bradycardia"},{"rate":"5-10","effect":"Gynecomastia (spironolactone)"},{"rate":"5-15","effect":"Hypotension"},{"rate":"5-10","effect":"Erectile dysfunction"}]},"_chembl":{"chemblId":"CHEMBL1393","moleculeType":"Small molecule","molecularWeight":"416.58"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Spironolactone blocks aldosterone receptors in the collecting duct, promoting sodium and water excretion while retaining potassium, thereby reducing blood volume and blood pressure. Beta-blockers reduce heart rate and contractility, decreasing cardiac oxygen demand and blood pressure. Together, these agents are commonly used in heart failure and hypertension management to improve outcomes and reduce neurohormonal activation.","oneSentence":"This is a combination therapy using spironolactone (a potassium-sparing diuretic and aldosterone antagonist) and beta-blockers to reduce fluid retention, lower blood pressure, and decrease cardiac workload.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:37:58.235Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Heart failure with reduced ejection fraction"},{"name":"Hypertension"},{"name":"Post-myocardial infarction management"},{"name":"Aldosteronism"}]},"trialDetails":[{"nctId":"NCT00527059","phase":"PHASE4","title":"Renal Effects of Levosimendan in Patients Admitted With Acute Decompensated Heart Failure","status":"UNKNOWN","sponsor":"University of Roma La Sapienza","startDate":"2007-10","conditions":"Heart Failure, Renal Insufficiency","enrollment":21}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"spironolactone, beta-blockers,ecc","genericName":"spironolactone, beta-blockers,ecc","companyName":"University of Roma La Sapienza","companyId":"university-of-roma-la-sapienza","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This is a combination therapy using spironolactone (a potassium-sparing diuretic and aldosterone antagonist) and beta-blockers to reduce fluid retention, lower blood pressure, and decrease cardiac workload. Used for Heart failure with reduced ejection fraction, Hypertension, Post-myocardial infarction management.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}